Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN III 30 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN III 30 versus LIQREV.
LIPOSYN III 30% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn III 30% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories for parenteral nutrition. It serves as a substrate for energy production and component of cell membranes.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Adults: 1-2 g/kg/day intravenously, not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 30 minutes, increase to 100-125 mL/h as tolerated.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
The terminal elimination half-life of the triglyceride component is approximately 30 minutes (range 20-40 minutes) in patients with normal lipid metabolism. In critically ill patients or those with impaired clearance, half-life may be prolonged.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Liposyn III 30% is a fat emulsion; its components are metabolized like endogenous triglycerides. Clearance involves hydrolysis by lipoprotein lipase, releasing free fatty acids which are oxidized or stored. Less than 1% is excreted unchanged in urine; a small fraction is excreted in bile/feces. No significant renal or biliary elimination of intact emulsion.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion